NeuroAiDTM (MLC601, MLC901): A New Bench-to-Bedside Approach to the Treatment of Ischemic Brain Injury
Michel Dib *
Department of Neurology, Pitié-Salpêtrière Hospital ,47-83, boulevard de l'Hôpital - 75013 Paris, France
Ihsan K. Abdul Zahra
Department of Medicine, Hawler College of Medicine and Teaching Hospital, Erbil, Iraq
Siwaporn Chankrachang
Division of Neurology, Department of Medicine, Chiang Mai University, 110 Intavaroros, Amphur Muang, Chiang Mai 50200, Thailand
Anna Czlonkowska
Department of Neurology, Neurological and Psychiatry Institute, Street Sobieskiego 9,02-957 Warsaw, Poland
Anatoly I. Fedin
Neurology Department, Pirogov Russian National Research Medical University, 1 Ostrovitianova str.117997 Moscow, Russia
Hovhannes Manvelyan
Neurology Department, Yerevan State Medical University, Koryunistr, 2, Yerevan374025, Armenia
Aurelio Mendez
Department of Neurology, Instituto Nacional de Cardiología Ignacio Chavez, Juan Badiano #1, Sección XVI, Tlalpan, México, D.F., 14080, Mexico City, Mexico
Ivan Milanov
Multiprofile Hospital for Active Treatment in Neurology and Psychiatry, Accredited University Hospital, 1, Louben Roussev str., Sofia 1113, Bulgaria
Yomi Ogun
Department of Medicine/Neurology, Obafemi Awolowo College of Health Sciences, OOUTH Sagamu, Ogun State, Nigeria
Hossein Pakdaman
Neurology Department, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran
Dodik Tugasworo
Neurology Department, Dr Kariadi Hospital, Jalan Dr. Sutomo No16, Semarang, Indonesia
*Author to whom correspondence should be addressed.
Abstract
Background and Aim: Faced with the public health burden of stroke and brain damage, various synthetic drugs with different pharmacological targets have been investigated in an attempt to improve clinical outcome, but many failed in clinical trials. In this article, we aimed to outline the current knowledge on the main clinical and pharmacological data of NeuroAiDTM (MLC601, MLC901), a novel product combining extracts from natural sources, in improving neurological and functional recovery after a stroke.
Methods: We reviewed and summarized important findings reported in pre-clinical and clinical publications that investigated the role of NeuroAiDTM in stroke.
Summary of Review: NeuroAiDTM has shown significant pharmacological properties for neuroprotection and neurorestoration in preclinical studies involving animal and cellular models of focal and global ischemia. Clinical studies have shown safety and efficacy data for enhancing neurorecovery beyond acute neuroprotection by reducing long-term neurological deficits and improving functional outcome in post-stroke patients.
Conclusion: NeuroAiDTM offers a safe therapeutic solution likely through a multi-modal mode of action in reducing the burden of ischemic brain injury.
Keywords: NeuroAiD, MLC601, MLC901, stroke, stroke recovery, neuroprotection, neuroplasticity